The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...

Polyphor halts Phase III enrollment of pneumonia therapy Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...

Belgian company Promethera added new Japanese and Korean investors in its series D round Monday, as part of its focus on growing its Asia network to leverage the "openness" to stem cell therapies in the...

Promethera said its HepaStem cell therapy comprising human adult liver-derived mesenchymal stem cells achieved a positive safety profile and improved three measures of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver...

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the...